(7-chloro-6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone | 1176026-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (7-chloro-6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone
• CAS: 1176026-32-6
• 化学式: C₁₉H₁₈ClNO₅
• 分子量: 375.809
• InChiKey: IVATXGUPICYMJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  69.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (6-methoxy-1H-indol-3-yl)(3,4,5-trimethoxyphenyl)methanone 在 N-氯代丁二酰亚胺 作用下， 以 叔丁醇 为溶剂， 反应 16.5h， 以53%的产率得到(7-chloro-6-methoxy-1H-indol-3-yl)-(3,4,5-trimethoxyphenyl)methanone
  参考文献：
  名称：

  Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach

  摘要：

  BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterism principle. Metabolites of 2, proposed from in vitro human microsome studies, were synthesized, leading to the identification of metabolitc-derived analogue 10 with 40-350 pM potency against various cancer cell lines. Insights gained from the major inactive metabolite of 2 led to the development of 29, with better pharmacokinetics and improved potency in the tumor xenograft model than 2.

  DOI：

  10.1021/jm900060s

文献信息

• Synthesis and Evaluation of 3-Aroylindoles as Anticancer Agents: Metabolite Approach
  作者：Yu-Shan Wu、Mohane Selvaraj Coumar、Jang-Yang Chang、Hsu-Yi Sun、Fu-Ming Kuo、Ching-Chuan Kuo、Ying-Jun Chen、Chi-Yen Chang、Chia-Ling Hsiao、Jing-Ping Liou、Ching-Ping Chen、Hsien-Tsung Yao、Yi-Kun Chiang、Uan-Kang Tan、Chiung-Tong Chen、Chang-Ying Chu、Su-Ying Wu、Teng-Kuang Yeh、Chin-Yu Lin、Hsing-Pang Hsieh

  DOI：10.1021/jm900060s

  日期：2009.8.13

  BPR0L075 (2) is a potential anticancer drug candidate designed from Combretastatin A-4 (1) based on the bioisosterism principle. Metabolites of 2, proposed from in vitro human microsome studies, were synthesized, leading to the identification of metabolitc-derived analogue 10 with 40-350 pM potency against various cancer cell lines. Insights gained from the major inactive metabolite of 2 led to the development of 29, with better pharmacokinetics and improved potency in the tumor xenograft model than 2.